Metagenomi Therapeutics, Inc. (MGX) — Operating Cash Flow
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$88.89M | +18.5% |
| 2024 | -$109.07M | -19.3% |
| 2023 | -$91.41M | — |
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$88.89M | +18.5% |
| 2024 | -$109.07M | -19.3% |
| 2023 | -$91.41M | — |